Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml - injection - excipient ingredients: water for injections - vinorelbine tartrate is indicated in the treatment of advanced non-small cell lung cancer (nsclc), as a single agent or in combination. vinorelbine tartrate is also indicated for the treatment of patients with metastatic breast cancer who have failed standard first-line chemotherapy for metastatic disease. in addition, vinorelbine tartrate is indicated for the treatment of patients with metastatic breast cancer who have relapsed within 6 months of anthracycline-based adjuvant therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - paclitaxel, quantity: 6 mg/ml - injection - excipient ingredients: ethanol absolute; peg-35 castor oil; citric acid - ovarian cancer: ??in first-line chemotherapy paclitaxel is indicated for the treatment of patients with advanced disease or a residual disease (>1 cm) after initial laparotomy, in combination with cisplatin. ??in second-line chemotherapy paclitaxel is indicated in the treatment of metastatic carcinoma of the ovary after failure of standard platinum based therapy. breast cancer: ??in the adjuvant setting, paclitaxel is indicated for the treatment of patients with node-positive breast carcinoma following anthracycline and cyclophosphamide (ac) therapy. adjuvant treatment with paclitaxel should be regarded as an alternative to extended ac therapy. ??paclitaxel is indicated for the initial treatment of locally advanced or metastatic breast cancer either in combination with an anthracycline in patients for whom anthracycline therapy is suitable, or in combination with trastuzumab, in patients who over-express human epidermal growth factor receptor 2 (her-2) at a 3+ level as determined by immunohistochemistry and for whom an anthracycline is not suitable. ??as a single agent, treatment of metastatic carcinoma of the breast in patients who have failed to respond adequately to standard treatment with anthracyclines or in whom anthracycline therapy has not been appropriate, or relapse within 6 months of adjuvant chemotherapy. advanced non-small cell lung cancer (nsclc): ??paclitaxel, in combination with cisplatin, is indicated for the treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgical intervention and/or radiation therapy. aids-related kaposi?s sarcoma (ks): ??paclitaxel is indicated for the treatment of patients with advanced aids-related ks who have failed prior liposomal anthracycline therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - oxaliplatin, quantity: 5 mg/ml - injection - excipient ingredients: tartaric acid; sodium hydroxide; water for injections - oxaliplatin is an anti-cancer drug and is used to treat metastatic (advanced) cancer of the colon (large bowel) or rectum (back passage), or as additional treatment following surgery to remove a tumor (growth) in the colon. it is used in combination with other anti-cancer medicines called 5-fluorouracil (5-fu) and folinic acid (fa).

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - oxaliplatin, quantity: 5 mg/ml - injection - excipient ingredients: water for injections; sodium hydroxide; tartaric acid - oxaliplatin is an anti-cancer drug and is used to treat metastatic (advanced) cancer of the colon (large bowel) or rectum (back passage), or as additional treatment following surgery to remove a tumour (growth) in the colon. it is used in combination with other anti-cancer medicines called 5-fluorouracil (5-fu) and folinic acid (fa).

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - epirubicin hydrochloride is used in the treatment of: - breast, ovarian, stomach, lung and colorectal cancer - malignant lymphoma e.g. hodgkin's disease and non-hodgkin's lymphoma - multiple myeloma - non-invasive bladder cancer epirubicin is also used to help prevent recurrence of bladder cancer after surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - epirubicin hydrochloride is used in the treatment of: - breast, ovarian, stomach, lung and colorectal cancer - malignant lymphoma e.g. hodgkin's disease and non-hodgkin's lymphoma - multiple myeloma - non-invasive bladder cancer epirubicin is also used to help prevent recurrence of bladder cancer after surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - epirubicin hydrochloride, quantity: 2 mg/ml - injection - excipient ingredients: sodium chloride; water for injections; hydrochloric acid - epirubicin hydrochloride is used in the treatment of: - breast, ovarian, stomach, lung and colorectal cancer - malignant lymphoma e.g. hodgkin's disease and non-hodgkin's lymphoma - multiple myeloma - non-invasive bladder cancer epirubicin is also used to help prevent recurrence of bladder cancer after surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - sodium chloride, quantity: 2.6 mg/ml; methotrexate, quantity: 25 mg/ml - injection - excipient ingredients: benzyl alcohol; sodium hydroxide; water for injections; hydrochloric acid - methotrexate injection usp belongs to a group of medicines known as anti-metabolites. it is used in high doses to treat certain types of cancers, including breast cancer, non-hodgkin's lymphoma and leukemia. at lower doses, it may also be used to treat severe psoriasis and severe rheumatoid arthritis.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - carboplatin, quantity: 10 mg/ml - injection - excipient ingredients: water for injections - carboplatin injection is indicated for the treatment of ovarian cancer and small cell lung carcinoma.

Australia - English - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - carboplatin, quantity: 10 mg/ml - injection - excipient ingredients: water for injections - carboplatin injection is indicated for the treatment of ovarian cancer of epithelial origin in first line therapy, and in second line therapy after other treatments have failed.